Biodesix announces common stock purchase agreement for up to $50 million with lincoln park capital

Boulder, colo.--(business wire)---- $bdsx #patientsfirst--biodesix, inc. (nasdaq: bdsx), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced it has entered into a purchase agreement for the issuance and sale of its common stock, from time to time, of up to $50 million with lincoln park capital fund, llc (lpc), a chicago-based institutional investor. under the terms of the purchase agreement, biodesix will have the right at its sole discretion, but not the obligation, to sell
BDSX Ratings Summary
BDSX Quant Ranking